The war in Ukraine brings suffering and trauma, which naturally leads to cases of post-traumatic stress disorder (PTSD) among soldiers and civilians.
A new report has been released by Canada’s Senate Subcommittee on Veterans Affairs – ‘The Time Is Now: Granting Equitable Access to Psychedelic Assisted Therapies’ –...
MAPS PBC has published anticipated results from its Phase 3b study that could bring MDMA-assisted therapy closer to Food and Drug Administration (FDA) approval by 2024...
Silo Pharma has announced it has advanced the formulation development for its therapeutic drug, SPC-15, which utilises ketamine.
With an explosion in research looking at psychedelic therapy for a number of mental health conditions, FDA approval for MDMA-assisted psychotherapy for PTSD is anticipated for...
A new study has investigated whether psilocybin could be the key to restore ‘fear extinction’ and thus help treat post-traumatic stress disorder (PTSD).
PTSD is typically thought of in relation to veterans of recent wars and victims of abuse, and psychedelics have been researched in the last decades to help with...
Study participants demonstrated a durable response at least six months, and in some cases a year or more, after their final MDMA-assisted therapy session during the...
COMPASS Pathways is recruiting participants for its trial investigating the safety and tolerability of its psilocybin formula – COMP360 – for post-traumatic stress disorder (PTSD).
Results from MAPS PBC’s study have demonstrated a biological correlation between a reduction in PTSD severity and treatment with MDMA-assisted therapy in veterans and first responders.
